Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 7:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 459 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: HYPERCHOLESTEROLEMIA Clear all
Completed Phase 2 Interventional

Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects

NCT01412034
View directory record Official record
Conditions
Homozygous Familial Hypercholesterolemia
Interventions
CER-001
Drug
Lead sponsor
Cerenis Therapeutics, SA
Industry
Eligibility
12 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Hartford, Connecticut • North Massapequa, New York
Source: ClinicalTrials.gov public record
Updated Aug 18, 2015 · Synced Sep 30, 2026, 7:26 AM EDT
Completed Phase 3 Interventional Results available

Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome

NCT04873934
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Inclisiran
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
88
States / cities
Jonesboro, Arkansas • Bakersfield, California • Fresno, California + 75 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Sep 30, 2026, 7:26 AM EDT
Completed Phase 3 Interventional Results available

A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia

NCT01968980
View directory record Official record
Conditions
Heterozygous Familial Hypercholesterolemia
Interventions
Bococizumab (PF-04950615;RN316), Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
22
States / cities
Los Angeles, California • Hartford, Connecticut • Hialeah, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Sep 30, 2026, 7:26 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary Hypercholesterolemia

NCT01288469
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab, Placebo (for alirocumab), Atorvastatin, Placebo (for atorvastatin)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
20
States / cities
Mesa, Arizona • Tucson, Arizona • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced Sep 30, 2026, 7:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of Alirocumab SAR236553 (REGN727)

NCT01448304
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
alirocumab SAR236553 (REGN727)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 28, 2013 · Synced Sep 30, 2026, 7:26 AM EDT
Completed Not applicable Interventional

Evaluating Weight Loss Programs for Obese People at Risk for Heart Disease (The POWER Study)

NCT00783315
View directory record Official record
Conditions
Obesity
Interventions
Call-Center Directed (CCD) Weight Loss Program, In-Person Directed (IPD) Weight Loss Program, Self-Directed Weight Loss Program
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Sep 30, 2026, 7:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Whey Protein Comparisons for Blood Lipid Effects

NCT07101263
View directory record Official record
Conditions
Cholesterol
Interventions
Standard whey, Hydrolyzed whey
Dietary Supplement
Lead sponsor
Medinutra LLC
Other
Eligibility
21 Years to 59 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Dublin, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 30, 2026, 7:26 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia

NCT02739984
View directory record Official record
Conditions
Hypercholesterolemia, Mixed Dyslipidemia, Type 2 Diabetes
Interventions
Evolocumab, Placebo to Evolocumab
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
46
States / cities
Tuscumbia, Alabama • Phoenix, Arizona • Lomita, California + 39 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Sep 30, 2026, 7:26 AM EDT
Completed No phase listed Observational

A Real-world Study to Assess the Characteristics and Long-term Effectiveness of Inclisiran in Chinese Adult Patients

NCT06595069
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Not listed
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Sep 30, 2026, 7:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Black Tea Intake on Serum Lipids

NCT01882283
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Tea Treatment Group, Placebo
Dietary Supplement
Lead sponsor
University of Minnesota
Other
Eligibility
45 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Sep 30, 2026, 7:26 AM EDT
Completed Phase 3 Interventional Results available

A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)

NCT05952869
View directory record Official record
Conditions
Hypercholesterolemia, Familial Hypercholesterolemia
Interventions
Enlicitide Decanoate, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
13
States / cities
Daphne, Alabama • Boca Raton, Florida • Cutler Bay, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 30, 2026, 7:26 AM EDT
Completed Phase 2 Interventional Results available

A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)

NCT05694260
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Bempedoic acid
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
8
States / cities
Los Angeles, California • West Covina, California • Boca Raton, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Sep 30, 2026, 7:26 AM EDT
Completed Phase 2 Interventional

A Study of the Safety, Pharmacokinetic Drug Interaction and Efficacy of ETC-1002 and Atorvastatin in Subjects With Hypercholesterolemia

NCT01779453
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
ETC-1002, Placebo, Atorvastatin
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Indianapolis, Indiana • Louisville, Kentucky • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 29, 2019 · Synced Sep 30, 2026, 7:26 AM EDT
Completed Phase 4 Interventional

Evaluation of Combination Cholesterol Treatments in Patients With High Cholesterol.

NCT00249938
View directory record Official record
Conditions
Hyperlipidemia, Dyslipidemia
Interventions
Minute Maid Heart Wise orange juice, Welchol
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Sep 30, 2026, 7:26 AM EDT
Completed Phase 3 Interventional Results available

Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

NCT03409744
View directory record Official record
Conditions
Homozygous Familial Hypercholesterolemia
Interventions
evinacumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
9
States / cities
Los Angeles, California • Boca Raton, Florida • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Sep 30, 2026, 7:26 AM EDT
Withdrawn Not applicable Interventional

Effects of Mixed Exercise Regime and L-Carnitine Supplementation in HIV Patients on HAART

NCT00572429
View directory record Official record
Conditions
HIV Infections, Hyperlipidemia, Exercise
Interventions
l-carnitine
Dietary Supplement
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2012 · Synced Sep 30, 2026, 7:26 AM EDT
Completed Phase 2 Interventional Results available

Supplements, Placebo, or Rosuvastatin Study

NCT04846231
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Fish Oil, Cinnamon, Garlique,Turmeric, Plant Sterol, Red Yeast Rice, Rosuvastatin, Placebo
Dietary Supplement · Drug · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
40 Years to 75 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Sep 30, 2026, 7:26 AM EDT
Completed Phase 3 Interventional

Carotid B-Mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrpib/Atorvastatin to Atorvastatin Alone.

NCT00136981
View directory record Official record
Conditions
Hypercholesterolemia, Familial, Hyperlipidemia
Interventions
torcetrapib/atorvastatin, atorvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
7
States / cities
Hartford, Connecticut • Boston, Massachusetts • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2015 · Synced Sep 30, 2026, 7:26 AM EDT
Completed Phase 2 Interventional Results available

An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol

NCT03060577
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease, Symptomatic Atherosclerosis, Type2 Diabetes, Familial Hypercholesterolemia
Interventions
Inclisiran, Evolocumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
8
States / cities
Jacksonville, Florida • Indianapolis, Indiana • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2023 · Synced Sep 30, 2026, 7:26 AM EDT
Completed Phase 2 Interventional Results available

Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia

NCT00477594
View directory record Official record
Conditions
Lipid Metabolism, Inborn Errors, Hypercholesterolemia, Autosomal Dominant, Hyperlipidemias, Metabolic Diseases, Hyperlipoproteinemia Type II, Metabolism, Inborn Errors, Genetic Diseases, Inborn, Infant, Newborn, Diseases, Metabolic Disorder, Congenital Abnormalities, Hypercholesterolemia, Hyperlipoproteinemias, Dyslipidemias, Lipid Metabolism Disorders
Interventions
mipomersen sodium
Drug
Lead sponsor
Kastle Therapeutics, LLC
Industry
Eligibility
12 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
5
States / cities
Chicago, Illinois • Auburn, Maine • Biddeford, Maine + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2016 · Synced Sep 30, 2026, 7:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia

NCT01243151
View directory record Official record
Conditions
Hypercholesterolemia, Dyslipidemia
Interventions
PF-04950615 (RN316)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
9
States / cities
Culver City, California • Glendale, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Sep 30, 2026, 7:26 AM EDT
Completed No phase listed Observational

Effects of Low-density Lipoprotein (LDL) Apheresis on Inflammatory and Lipid Markers

NCT01138371
View directory record Official record
Conditions
Familial Hypercholesterolemia
Interventions
LDL Apheresis
Procedure
Lead sponsor
Emory University
Other
Eligibility
3 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Sep 30, 2026, 7:26 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Effects of a Supplement Derived From Palm Oil on Cholesterol Levels in the Blood

NCT02634606
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Gamma Delta Tocotrienols - Low Dose, Gamma Delta Tocotrienols - High Dose, Sugar Pill
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
35 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Sep 30, 2026, 7:26 AM EDT
Completed No phase listed Observational

Cardiovascular Evaluation of Patients With High Cholesterol and Normal Volunteers

NCT00001204
View directory record Official record
Conditions
Homozygous Familial Hypercholesterolemic
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 70 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1992
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Sep 30, 2026, 7:26 AM EDT